• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病毒逃逸突变不能解释 RhCMV/SIV 疫苗接种恒河猴对 SIVmac239 挑战无保护作用。

Viral escape mutations do not account for non-protection from SIVmac239 challenge in RhCMV/SIV vaccinated rhesus macaques.

机构信息

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

出版信息

Front Immunol. 2024 Aug 7;15:1444621. doi: 10.3389/fimmu.2024.1444621. eCollection 2024.

DOI:10.3389/fimmu.2024.1444621
PMID:39170621
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11336698/
Abstract

Simian immunodeficiency virus (SIV) vaccines based upon 68-1 Rhesus Cytomegalovirus (RhCMV) vectors show remarkable protection against pathogenic SIVmac239 challenge. Across multiple independent rhesus macaque (RM) challenge studies, nearly 60% of vaccinated RM show early, complete arrest of SIVmac239 replication after effective challenge, whereas the remainder show progressive infection similar to controls. Here, we performed viral sequencing to determine whether the failure to control viral replication in non-protected RMs is associated with the acquisition of viral escape mutations. While low level viral mutations accumulated in all animals by 28 days-post-challenge, which is after the establishment of viral control in protected animals, the dominant circulating virus in virtually all unprotected RMs was nearly identical to the challenge stock, and there was no difference in mutation patterns between this cohort and unvaccinated controls. These data definitively demonstrate that viral mutation does not explain lack of viral control in RMs not protected by RhCMV/SIV vaccination. We further demonstrate that during chronic infection RhCMV/SIV vaccinated RMs do not acquire escape mutation in epitopes targeted by RhCMV/SIV, but instead display mutation in canonical MHC-Ia epitopes similar to unvaccinated RMs. This suggests that after the initial failure of viral control, unconventional T cell responses induced by 68-1 RhCMV/SIV vaccination do not exert strong selective pressure on systemically replicating SIV.

摘要

猿猴免疫缺陷病毒(SIV)基于 68-1 恒河猴巨细胞病毒(RhCMV)载体的疫苗在预防致病性 SIVmac239 感染方面显示出显著的保护作用。在多个独立的恒河猴(RM)挑战研究中,近 60%的接种 RM 在有效接种后早期完全阻止了 SIVmac239 的复制,而其余的 RM 则表现出与对照相似的进行性感染。在这里,我们进行了病毒测序,以确定在未受保护的 RM 中未能控制病毒复制是否与获得病毒逃逸突变有关。虽然所有动物在接种后 28 天(即保护动物建立病毒控制后)都会积累低水平的病毒突变,但在几乎所有未受保护的 RM 中,主要循环病毒几乎与挑战株相同,并且在这一组和未接种对照之间,突变模式没有差异。这些数据明确表明,病毒突变不能解释 RhCMV/SIV 疫苗未保护的 RM 中病毒控制的失败。我们进一步表明,在慢性感染期间,RhCMV/SIV 接种的 RM 不会在 RhCMV/SIV 靶向的表位中获得逃逸突变,而是在与未接种 RM 相似的经典 MHC-Ia 表位中显示突变。这表明,在最初的病毒控制失败后,68-1 RhCMV/SIV 疫苗诱导的非常规 T 细胞反应不会对全身复制的 SIV 产生强烈的选择压力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/6e80106d123c/fimmu-15-1444621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/a59225b833be/fimmu-15-1444621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/4dbd27c0bee4/fimmu-15-1444621-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/6cb67af73e67/fimmu-15-1444621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/6e80106d123c/fimmu-15-1444621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/a59225b833be/fimmu-15-1444621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/4dbd27c0bee4/fimmu-15-1444621-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/6cb67af73e67/fimmu-15-1444621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7202/11336698/6e80106d123c/fimmu-15-1444621-g004.jpg

相似文献

1
Viral escape mutations do not account for non-protection from SIVmac239 challenge in RhCMV/SIV vaccinated rhesus macaques.病毒逃逸突变不能解释 RhCMV/SIV 疫苗接种恒河猴对 SIVmac239 挑战无保护作用。
Front Immunol. 2024 Aug 7;15:1444621. doi: 10.3389/fimmu.2024.1444621. eCollection 2024.
2
Pre-challenge gut microbial signature predicts RhCMV/SIV vaccine efficacy in rhesus macaques.预先挑战的肠道微生物特征可预测恒河猴 CMV/SIV 疫苗在恒河猴中的功效。
Microbiol Spectr. 2024 Nov 5;12(11):e0128524. doi: 10.1128/spectrum.01285-24. Epub 2024 Sep 30.
3
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.一种减毒活 RhCMV/SIV 疫苗对异源 SIV 攻击显示出长期疗效。
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aaw2607.
4
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.效应记忆 T 细胞疫苗对高致病性 SIV 的早期深度控制。
Nature. 2011 May 26;473(7348):523-7. doi: 10.1038/nature10003. Epub 2011 May 11.
5
Rhesus Macaques Vaccinated with , , and Manifest Early Control of SIVmac239 Replication.恒河猴接种 、 、 和 后,早期控制 SIVmac239 复制。
J Virol. 2018 Jul 31;92(16). doi: 10.1128/JVI.00690-18. Print 2018 Aug 15.
6
The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in Rhesus Macaques.疫苗诱导的 T 细胞反应频率并不预测恒河猴重复经直肠 SIVmac239 挑战后的获得率。
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.01626-18. Print 2019 Mar 1.
7
Rhesus Cytomegalovirus-Specific CD8 Cytotoxic T Lymphocytes Do Not Become Functionally Exhausted in Chronic SIVmac239 Infection.恒河猴巨细胞病毒特异性 CD8 细胞毒性 T 淋巴细胞在慢性 SIVmac239 感染中不会发生功能衰竭。
Front Immunol. 2020 Aug 12;11:1960. doi: 10.3389/fimmu.2020.01960. eCollection 2020.
8
Immune clearance of highly pathogenic SIV infection.高致病性 SIV 感染的免疫清除。
Nature. 2013 Oct 3;502(7469):100-4. doi: 10.1038/nature12519. Epub 2013 Sep 11.
9
Recombinant Herpesvirus Vectors: Durable Immune Responses and Durable Protection against Simian Immunodeficiency Virus SIVmac239 Acquisition.重组单纯疱疹病毒载体:持久的免疫应答和对猴免疫缺陷病毒 SIVmac239 获得性感染的持久保护。
J Virol. 2021 Jun 24;95(14):e0033021. doi: 10.1128/JVI.00330-21.
10
Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.白细胞介素-15 反应特征可预测 RhCMV/SIV 疫苗的疗效。
PLoS Pathog. 2021 Jul 6;17(7):e1009278. doi: 10.1371/journal.ppat.1009278. eCollection 2021 Jul.

本文引用的文献

1
Programming cytomegalovirus as an HIV vaccine.将巨细胞病毒作为 HIV 疫苗进行编程。
Trends Immunol. 2023 Apr;44(4):287-304. doi: 10.1016/j.it.2023.02.001. Epub 2023 Mar 7.
2
Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV.晚期基因表达缺陷型巨细胞病毒载体引发的传统 T 细胞不能预防 SIV。
JCI Insight. 2023 Mar 22;8(6):e164692. doi: 10.1172/jci.insight.164692.
3
Myeloid cell tropism enables MHC-E-restricted CD8 T cell priming and vaccine efficacy by the RhCMV/SIV vaccine.
髓系细胞嗜性通过 RhCMV/SIV 疫苗促进 MHC-E 限制性 CD8 T 细胞的初始免疫和疫苗效力。
Sci Immunol. 2022 Jun 24;7(72):eabn9301. doi: 10.1126/sciimmunol.abn9301. Epub 2022 Jun 17.
4
HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens.HIV-1与新型冠状病毒:两种大流行病原体的进化模式
Cell Host Microbe. 2021 Jul 14;29(7):1093-1110. doi: 10.1016/j.chom.2021.05.012. Epub 2021 Jun 3.
5
Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.白细胞介素-15 反应特征可预测 RhCMV/SIV 疫苗的疗效。
PLoS Pathog. 2021 Jul 6;17(7):e1009278. doi: 10.1371/journal.ppat.1009278. eCollection 2021 Jul.
6
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.病毒诱饵配体对 MHC-E 转运的调节是 RhCMV/SIV 疫苗效力所必需的。
Science. 2021 Apr 30;372(6541). doi: 10.1126/science.abe9233. Epub 2021 Mar 25.
7
Cytomegaloviral determinants of CD8 T cell programming and RhCMV/SIV vaccine efficacy.巨细胞病毒决定簇对 CD8 T 细胞编程和 RhCMV/SIV 疫苗效力的影响。
Sci Immunol. 2021 Mar 25;6(57). doi: 10.1126/sciimmunol.abg5413.
8
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.一种减毒活 RhCMV/SIV 疫苗对异源 SIV 攻击显示出长期疗效。
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aaw2607.
9
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.早期抗逆转录病毒疗法可限制 SIV 储存库的建立,从而延迟或预防治疗后病毒反弹。
Nat Med. 2018 Sep;24(9):1430-1440. doi: 10.1038/s41591-018-0130-7. Epub 2018 Aug 6.
10
Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E.由主要组织相容性复合体E限制的广泛靶向性CD8⁺T细胞反应
Science. 2016 Feb 12;351(6274):714-20. doi: 10.1126/science.aac9475. Epub 2016 Jan 21.